Clinical Trial Update: A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluating the efficacy and safety of HBM9161 in patients with primary immune thrombocytopenic purpura (ITP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• HBM9161

Snippet

Sponsor: Harbour BioMed (Guangzhou) Co. Ltd. | Conditions: Primary Immune Thrombocytopenic Purpura | Phase 2, Phase 3 | Status: COMPLETED